JP2023533204A - 乳がんワクチン - Google Patents

乳がんワクチン Download PDF

Info

Publication number
JP2023533204A
JP2023533204A JP2022580102A JP2022580102A JP2023533204A JP 2023533204 A JP2023533204 A JP 2023533204A JP 2022580102 A JP2022580102 A JP 2022580102A JP 2022580102 A JP2022580102 A JP 2022580102A JP 2023533204 A JP2023533204 A JP 2023533204A
Authority
JP
Japan
Prior art keywords
immunogenic composition
her2
magea3
survivin
htert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533204A5 (enExample
Inventor
キース エル． ヌトソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Breast Cancer Coalition
Original Assignee
National Breast Cancer Coalition
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Breast Cancer Coalition filed Critical National Breast Cancer Coalition
Publication of JP2023533204A publication Critical patent/JP2023533204A/ja
Publication of JP2023533204A5 publication Critical patent/JP2023533204A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022580102A 2020-06-26 2021-06-25 乳がんワクチン Pending JP2023533204A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044675P 2020-06-26 2020-06-26
US63/044,675 2020-06-26
PCT/US2021/039046 WO2021263081A2 (en) 2020-06-26 2021-06-25 Breast cancer vaccine

Publications (2)

Publication Number Publication Date
JP2023533204A true JP2023533204A (ja) 2023-08-02
JP2023533204A5 JP2023533204A5 (enExample) 2024-07-02

Family

ID=79281909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580102A Pending JP2023533204A (ja) 2020-06-26 2021-06-25 乳がんワクチン

Country Status (6)

Country Link
US (1) US20230233656A1 (enExample)
EP (1) EP4171619A4 (enExample)
JP (1) JP2023533204A (enExample)
AU (1) AU2021294322A1 (enExample)
CA (1) CA3183774A1 (enExample)
WO (1) WO2021263081A2 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540672A (ja) * 2007-10-09 2010-12-24 キュアバック ゲーエムベーハー 肺癌治療用、特に非小細胞肺癌（ｎｓｃｌｃ）治療用組成物
JP2012502074A (ja) * 2008-09-30 2012-01-26 キュアバック ゲーエムベーハー 哺乳動物において免疫を賦活する応答を提供または増強するための複合化された（ｍ）ＲＮＡと裸のｍＲＮＡとを含んでいる組成物、およびその使用
JP2018509935A (ja) * 2015-03-16 2018-04-12 アマル セラピューティクス エスエー 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
WO2019038388A1 (en) * 2017-08-24 2019-02-28 Bavarian Nordic A/S POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
ES2771862T3 (es) * 2013-10-28 2020-07-07 Invectys Una vacuna de ADN que codifica telomerasa
EP3297658A1 (en) * 2015-05-18 2018-03-28 OncoQR ML GmbH Her2/neu immunogenic composition
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
CA3026345A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
US12390514B2 (en) * 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
KR20200027551A (ko) * 2017-07-11 2020-03-12 화이자 인코포레이티드 Cea muc1 및 tert를 포함하는 면역원성 조성물
CN110790840A (zh) * 2018-08-01 2020-02-14 三生国健药业（上海）股份有限公司 结合人her2的抗体、其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540672A (ja) * 2007-10-09 2010-12-24 キュアバック ゲーエムベーハー 肺癌治療用、特に非小細胞肺癌（ｎｓｃｌｃ）治療用組成物
JP2012502074A (ja) * 2008-09-30 2012-01-26 キュアバック ゲーエムベーハー 哺乳動物において免疫を賦活する応答を提供または増強するための複合化された（ｍ）ＲＮＡと裸のｍＲＮＡとを含んでいる組成物、およびその使用
JP2018509935A (ja) * 2015-03-16 2018-04-12 アマル セラピューティクス エスエー 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
WO2019038388A1 (en) * 2017-08-24 2019-02-28 Bavarian Nordic A/S POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY

Also Published As

Publication number Publication date
CA3183774A1 (en) 2021-12-30
WO2021263081A2 (en) 2021-12-30
US20230233656A1 (en) 2023-07-27
EP4171619A4 (en) 2024-08-07
WO2021263081A3 (en) 2022-02-10
EP4171619A2 (en) 2023-05-03
AU2021294322A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
KR102351555B1 (ko) Hpv 및 관련 질환용 면역 증강 치료 백신
US10272042B2 (en) Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
JP4741800B2 (ja) 抗血管新生活性療法
US10682402B2 (en) MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
US20040091995A1 (en) Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
JP5519477B2 (ja) Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
SA98190719B1 (ar) تركيب مشترك وطرق لعلاج نمو ورمي او سرطاني واستعادة او تنشيط تكون وتطور الدم
US12576143B2 (en) Teleost invariant chain cancer vaccine
CN105435218A (zh) 预防乳腺癌复发的疫苗
KR101810840B1 (ko) 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
WO2004044155A2 (en) MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
Park et al. Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice
US20050063952A1 (en) Immunogenic CEA
Mohit et al. The contribution of NT‐gp96 as an adjuvant for increasing HPV16 E7‐specific immunity in C57BL/6 mouse model
TWI740823B (zh) 疫苗組成物及其用途
JP2023533204A (ja) 乳がんワクチン
US20040191761A1 (en) Modified adenoviral E1A constructs and methods of use thereof
JP5890769B2 (ja) がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
CN113318225B (zh) 肿瘤免疫增强剂及其制法和应用
US8921534B2 (en) Enhancement of the immune response using CD36-binding domain
JP2025525504A (ja) タンパク質ベースの免疫アジュバントを組み込んだワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303